Leveraging Synthetic Biology for Resilient Pharma Supply Chains and Accessible Medicines

Antheia was founded in 2015 by Dr. Christina Smolke, CEO and Dr. Kristy Hawkins, CSO and is based in Menlo Park, California. Antheia’s co-founders are pioneers in the fields of synthetic biology and metabolic engineering and are applying these technologies to transform pharmaceutical supply chains in order to better support the needs of 21st century healthcare.
Live at SynBioBeta

Each year, SynBioBeta hosts the The Global Synthetic Biology Conference to showcase the latest cutting-edge developments in biology that are changing how we solve global problems. As a proud sponsor of this year’s event, we look forward to connecting with the synthetic biology community and sharing our progress toward transforming pharmaceutical supply chains.
Advancing the U.S. Bioeconomy and Building Resilient Pharmaceutical Supply Chains

We continue to see the U.S. government setting policy priorities that underscore the importance of both building a robust American bioeconomy and strengthening domestic pharmaceutical supply chains – two core pillars of Antheia’s business and technology.
Synthetic Chemistry in Pharma

Synthetic chemistry is an essential part of drug development, opening the door for scientists to create complex small molecules with specific properties. Small molecule drugs – including household staples like aspirin and acetaminophen – currently make up the bulk of approved pharmaceuticals to date.
Antheia Appoints John Nicols to Chair its Board of Directors

Antheia, the pharmaceutical ingredient manufacturer transforming supply chains, today announced the appointment of John Nicols to Chair its Board of Directors. Nicols joins co-founders Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO), as well as Ram Shriram and Dr. Patrick Yang on the Antheia Board of Directors.
Forbes’ Top Ten Women Founders in the Synthetic Biology Industry

Our co-founder and CEO, Christina Smolke, was named to Forbes’ list of top ten women founders taking the synthetic biology world by storm. From her groundbreaking work at Stanford to the impressive team she has built at Antheia, Christina has been a pioneer in the synbio space and we are thrilled to see her recognized alongside an esteemed group of individuals who are unlo
Introducing Jesse Ahrendt, Antheia’s SVP of Quality Assurance & Regulatory Affairs

We’ve recently welcomed Jesse Ahrendt, our new Senior Vice President of Quality Assurance and Regulatory Affairs, who will lead our quality and regulatory efforts. He brings 25 years of experience…
Synthetic Biology vs Synthetic Chemistry: A Primer

At Antheia, we spend a lot of time talking about synthetic biology due to the nature of our work engineering yeast to produce active pharmaceutical ingredients (APIs) and key starting materials (KSMs)…
Antheia’s 2022 in Review: A Year of Value

This year has been ripe with growth, major achievements, and opportunities to showcase who and what make Antheia the visionary business it is. Nearly eight years ago, we co-founded Antheia…
Drug Discovery and Development 2023 Predictions

Drug Discovery and Development highlighted key drug discovery and development predictions for 2023. Antheia was highlighted for its take on the synbio industry’s renewed focus on “how, as a global community…